Literature DB >> 19578344

Critical illness polyneuropathy and myopathy in the intensive care unit.

Wolfgang Zink1, Rainer Kollmar, Stefan Schwab.   

Abstract

Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) are major complications that occur in severely ill patients who require intensive care treatment. CIP and CIM affect the limb and respiratory muscles, and, as a consequence, they characteristically complicate weaning from the ventilator, increase the length of stay on the intensive care unit, and prolong physical rehabilitation. The basic pathophysiology of both disorders is complex and involves metabolic, inflammatory and bioenergetic alterations. It is unclear at present whether CIP and CIM are distinct entities, or whether they just represent different 'organ' manifestations of a common pathophysiological mechanism. This article provides an overview of the clinical and diagnostic features of CIP and CIM and discusses current pathophysiological and therapeutic concepts relating to these neuromuscular disorders.

Entities:  

Mesh:

Year:  2009        PMID: 19578344     DOI: 10.1038/nrneurol.2009.75

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  99 in total

1.  Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator.

Authors:  F S Leijten; A W De Weerd; D C Poortvliet; V A De Ridder; C Ulrich; J E Harink-De Weerd
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 2.  Dysregulation of sodium channel gating in critical illness myopathy.

Authors:  James W Teener; Mark M Rich
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

3.  Origin of ICU acquired paresis determined by direct muscle stimulation.

Authors:  J-P Lefaucheur; T Nordine; P Rodriguez; L Brochard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

Review 4.  Acute neuromuscular weakness in the intensive care unit.

Authors:  Bobby Varkey Maramattom; Eelco F M Wijdicks
Journal:  Crit Care Med       Date:  2006-11       Impact factor: 7.598

Review 5.  Neuromuscular sequelae of critical illness.

Authors:  Nicola Latronico; Indrit Shehu; Elisa Seghelini
Journal:  Curr Opin Crit Care       Date:  2005-08       Impact factor: 3.687

Review 6.  Critical illness myopathy: what is happening?

Authors:  Oliver Friedrich
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2006-07       Impact factor: 4.294

7.  Single-fiber electromyography, nerve conduction studies, and conventional electromyography in patients with critical-illness polyneuropathy: evidence for a lesion of terminal motor axons.

Authors:  J Schwarz; J Planck; J Briegel; A Straube
Journal:  Muscle Nerve       Date:  1997-06       Impact factor: 3.217

Review 8.  Critical illness polyneuropathy and myopathy: clinical features, risk factors and prognosis.

Authors:  L H Visser
Journal:  Eur J Neurol       Date:  2006-11       Impact factor: 6.089

Review 9.  Critical illness myopathy: sepsis-mediated failure of the peripheral nervous system.

Authors:  O Friedrich
Journal:  Eur J Anaesthesiol Suppl       Date:  2008

Review 10.  Insulin therapy for the critically ill patient.

Authors:  Greet Van den Berghe
Journal:  Clin Cornerstone       Date:  2003
View more
  27 in total

Review 1.  Intensive care unit-acquired weakness: implications for physical therapist management.

Authors:  Amy Nordon-Craft; Marc Moss; Dianna Quan; Margaret Schenkman
Journal:  Phys Ther       Date:  2012-01-26

Review 2.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 3.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

4.  Manual muscle testing: a method of measuring extremity muscle strength applied to critically ill patients.

Authors:  Nancy Ciesla; Victor Dinglas; Eddy Fan; Michelle Kho; Jill Kuramoto; Dale Needham
Journal:  J Vis Exp       Date:  2011-04-12       Impact factor: 1.355

5.  Early Physical Rehabilitation in the ICU: A Review for the Neurohospitalist.

Authors:  Pedro A Mendez-Tellez; Rasha Nusr; Dorianne Feldman; Dale M Needham
Journal:  Neurohospitalist       Date:  2012-07

Review 6.  [Critical illness polyneuropathy and critical illness myopathy].

Authors:  A Grimm; A Günther; O W Witte; H Axer
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-10-28       Impact factor: 0.840

7.  Acute and long-term dysphagia in critically ill patients with severe sepsis: results of a prospective controlled observational study.

Authors:  Joerg Zielske; Silvia Bohne; Frank M Brunkhorst; Hubertus Axer; Orlando Guntinas-Lichius
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-27       Impact factor: 2.503

Review 8.  [Critical illness polyneuropathy and myopathy as neurological complications of sepsis].

Authors:  R Kollmar
Journal:  Nervenarzt       Date:  2016-03       Impact factor: 1.214

Review 9.  Neurology of Sepsis.

Authors:  Rochelle Sweis; Jorge Ortiz; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

10.  ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.

Authors:  Thomas H Brannagan; Michaela Auer-Grumbach; John L Berk; Chiara Briani; Vera Bril; Teresa Coelho; Thibaud Damy; Angela Dispenzieri; Brian M Drachman; Nowell Fine; Hanna K Gaggin; Morie Gertz; Julian D Gillmore; Esther Gonzalez; Mazen Hanna; David R Hurwitz; Sami L Khella; Mathew S Maurer; Jose Nativi-Nicolau; Kemi Olugemo; Luis F Quintana; Andrew M Rosen; Hartmut H Schmidt; Jacqueline Shehata; Marcia Waddington-Cruz; Carol Whelan; Frederick L Ruberg
Journal:  Orphanet J Rare Dis       Date:  2021-05-06       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.